George D. Demetri, MD

Publications

• Demetri GD.Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.Semin Oncol. 2011 Apr;38 Suppl 1:S10-9.
  21419931
• Blay JY, Demetri GD.The evolution of a revolutionary class: extending benefits of tyrosine kinase inhibitors--introduction.Semin Oncol. 2011 Apr;38 Suppl 1:S1-2.
  21419930
• Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S.Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and
  21177764
• Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, Gaal J, Dahia PL, Liegl B, Ball ER, Raygada M, Lai AH, Kelly L, Hornick JL, , O'Sullivan M, de Krijger RR, Dinjens WN, Demetri GD, Antonescu CR, Fletcher JA, Helman L, Stratakis CA.Defects in succinat
  21173220
• Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Jänne PA.The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-trans
  21030459
• Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI.Crizotinib in ALK-rearranged inflammator
  20979472
• Demetri GD.Disease state awareness in sarcoma.Clin Adv Hematol Oncol. 2010 Aug;8(8):543-5.
  20966890
• Janeway KA, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD, Fletcher JA.Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification.Int J Cancer. 2010 Dec 1;127(11):2718-22.
  20162573
• Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, Delaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton
  20581298
• Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ.Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.Cancer Chemother Pharmacol.
  19967539
• Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.J Natl Com
  20457867
• Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, Ligon AH, Antonescu CR, Ramaiya NH, Demetri GD, Kwiatkowski DJ, Maki RG.Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: target
  20048174
• Raut CP, Wang Q, Manola J, Morgan JA, George S, Wagner AJ, Butrynski JE, Fletcher CD, Demetri GD, Bertagnolli MM.Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.Ann Surg Oncol. 2010 Feb;17(2):
  19898902
• Rubin BP, Blanke CD, Demetri GD, Dematteo RP, Fletcher CD, Goldblum JR, Lasota J, Lazar A, Maki RG, Miettinen M, Noffsinger A, Washington MK, Krausz T, .Protocol for the examination of specimens from patients with gastrointestinal stromal tumor.Arch Path
  20121601
• Theman TA, Hartzell TL, Sinha I, Polson K, Morgan J, Demetri GD, Orgill DP, George S.Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.J Clin Oncol. 2009 Nov 20;27(33):e198-200.
  19805684
• Ganjoo KN, Demetri GD, Jacobs C, Patel S.Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec.Leuk Lymphoma. 2009 Nov;50(11):1882-4.
  19883316
• Raut CP, Nucci MR, Wang Q, Manola J, Bertagnolli MM, Demetri GD, Morgan JA, Muto MG, Fletcher CD, George S.Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.Eur J Cancer. 2009 Nov;45(16):2818-24.
  19647426
• Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR.Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.Clin Cancer Res. 2009 Oct 1;15(19):6232-40.
  19789325
• Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, Shah MH, Verweij J, Baum CM, Demetri GD.Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib fol
  19737953
• Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG.Molecular target modulation, imaging, and clinical evaluation of gastrointestinal
  19737946
• Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P.A phase I study of single-agent nilotinib
  19723647
• Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A.Efficacy and safety of trabectedin in patients with advanced or metastatic
  19652065
• Benjamin RS, Debiec-Rychter M, Le Cesne A, Sleijfer S, Demetri GD, Joensuu H, Schöffski P, Poveda A.Gastrointestinal stromal tumors II: medical oncology and tumor response assessment.Semin Oncol. 2009 Aug;36(4):302-11.
  19664491
• Demetri GD,Wang Y,Wehrle E,Racine A,Nikolova Z,Blanke CD,Joensuu H,von Mehren M.Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors.J Clin Oncol. 2009 Jul 1;27(19):3141-7.
  19451435
• George S,Merriam P,Maki RG,Van den Abbeele AD,Yap JT,Akhurst T,Harmon DC,Bhuchar G,O'Mara MM,D'Adamo DR,Morgan J,Schwartz GK,Wagner AJ,Butrynski JE,Demetri GD,Keohan ML.Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointesti
  19451429
• Demetri GD.Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST.Clin Adv Hematol Oncol. 2009 Feb;7(2):S6-7.
  19391310
• Dematteo RP,Ballman KV,Antonescu CR,Maki RG,Pisters PW,Demetri GD,Blackstein ME,Blanke CD,von Mehren M,Brennan MF,Patel S,McCarter MD,Polikoff JA,Tan BR,Owzar K.Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumo
  19303137
• Gajiwala KS,Wu JC,Christensen J,Deshmukh GD,Diehl W,DiNitto JP,English JM,Greig MJ,He YA,Jacques SL,Lunney EA,McTigue M,Molina D,Quenzer T,Wells PA,Yu X,Zhang Y,Zou A,Emmett MR,Marshall AG,Zhang HM,Demetri GD.KIT kinase mutants show unique mechanisms of d
  19164557
• Winer E,Gralow J,Diller L,Karlan B,Loehrer P,Pierce L,Demetri G,Ganz P,Kramer B,Kris M,Markman M,Mayer R,Pfister D,Raghavan D,Ramsey S,Reaman G,Sandler H,Sawaya R,Schuchter L,Sweetenham J,Vahdat L,Schilsky RL.Clinical cancer advances 2008: major research
  19103723
• Quek R,Morgan JA,George S,Butrynski JE,Polson K,Meyer F,Demetri GD,Block SD.Small molecule tyrosine kinase inhibitor and depression.J Clin Oncol. 2009 Jan 10;27(2):312-3.
  19064960
• Jiang X,Zhou J,Yuen NK,Corless CL,Heinrich MC,Fletcher JA,Demetri GD,Widlund HR,Fisher DE,Hodi FS.Imatinib targeting of KIT-mutant oncoprotein in melanoma.Clin Cancer Res. 2008 Dec 1;14(23):7726-32.
  19047099
• Baker LH,Rowinsky EK,Mendelson D,Humerickhouse RA,Knight RA,Qian J,Carr RA,Gordon GB,Demetri GD.Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.J Clin Oncol. 2008 Dec
  18981463
• Heinrich MC,Maki RG,Corless CL,Antonescu CR,Harlow A,Griffith D,Town A,McKinley A,Ou WB,Fletcher JA,Fletcher CD,Huang X,Cohen DP,Baum CM,Demetri GD.Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in
  18955458
• Heinrich MC,Owzar K,Corless CL,Hollis D,Borden EC,Fletcher CD,Ryan CW,von Mehren M,Blanke CD,Rankin C,Benjamin RS,Bramwell VH,Demetri GD,Bertagnolli MM,Fletcher JA.Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase
  18955451
• Eisenberg BL,Harris J,Blanke CD,Demetri GD,Heinrich MC,Watson JC,Hoffman JP,Okuno S,Kane JM,von Mehren M.Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (G
  18942073
• Girnun GD,Chen L,Silvaggi J,Drapkin R,Chirieac LR,Padera RF,Upadhyay R,Vafai SB,Weissleder R,Mahmood U,Naseri E,Buckley S,Li D,Force J,McNamara K,Demetri G,Spiegelman BM,Wong KK.Regression of drug-resistant lung cancer by the combination of rosiglitazone
  18927287
• Haining WN,Davies J,Kanzler H,Drury L,Brenn T,Evans J,Angelosanto J,Rivoli S,Russell K,George S,Sims P,Neuberg D,Li X,Kutok J,Morgan J,Wen P,Demetri G,Coffman RL,Nadler LM.CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans
  18765557
• Bertagnolli MM,Morgan JA,Fletcher CD,Raut CP,Dileo P,Gill RR,Demetri GD,George S.Multimodality treatment of mesenteric desmoid tumours.Eur J Cancer. 2008 Nov;44(16):2404-10.
  18706807
• Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG.Phase II, Open-Label Study Evaluating th
  18451237
• Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE.Major response to imatinib mesylate in KIT-mutated melanoma.J Clin Oncol. 2008 Apr 20;26(12):2046-51.
  18421059
• Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD.A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.Journal of the Nationa
  18270341
• Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H.Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate f
  18235121
• Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC.Phase III randomized, intergroup trial assessing imatinib mesylate at two
  18235122
• Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA.Dose-escalation of filgrastim does not improve efficacy: Clinical
  18234424
• Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W Jr, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky
  18086794
• Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH.Cardiotoxicity associated with t
  18083403
• Demetri GD.Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.J Clin Invest. 2007 Dec;117(12):3650-3.
  18060025
• Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, Van den Abbeele AD.CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.AJR Am J Roentgenol. 2007 Dec;189(6):W324-
  18029844
• Ito H, Hornick JL, Bertagnolli MM, George S, Morgan JA, Baldini EH, Wagner AJ, Demetri GD, Raut CP.Leiomyosarcoma of the inferior vena cava: survival after aggressive management.Ann Surg Oncol. 2007 Dec;14(12):3534-41.
  17896156
• Zhu MJ, Ou WB, Fletcher CD, Cohen PS, Demetri GD, Fletcher JA.KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.Oncogene. 2007 Sep 27;26(44):6386-95.
  17452978
• Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, van Sonnenberg E, Demetri GD.Clonal evolution of resistance to imatinib in patients with metastatic gastroin
  17875769
• Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Rau
  17624289
• Faivre S, Demetri G, Sargent W, Raymond E.Molecular basis for sunitinib efficacy and future clinical development.Nat Rev Drug Discov. 2007 Sep;6(9):734-45. Review.
  17690708
• Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG.Efficacy of trabecte
  17586092
• Bauer S, Duensing A, Demetri GD, Fletcher JA.KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.Oncogene. 2007 Nov 29;26(54):7560-8.
  17546049
• Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, Deprimo SE, Shalinsky DR, Demetri GD, Heymach JV.Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gast
  17473195
• Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery
  17392811
• Dileo P, Morgan JA, Zahrieh D, Desai J, Salesi JM, Harmon DC, Quigley MT, Polson K, Demetri GD, George S.Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas : results of a phase II trial.Cancer. 2007 Mar 23
  17385194
• Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C,
  17293865
• Li D, Ji H, Zaghlul S, McNamara K, Liang MC, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Scott AM, Jungbluth AA, Cavenee WK, Old LJ, Demetri GD, Wong KK.Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dep
  17256054
• Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK.Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.Ann Intern Med. 2006 Nov 7;145(9):660-4.
  17088579
• Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.Efficacy and safety of sunitinib in patients with advanced gas
  17046465
• Bauer S, Yu LK, Demetri GD, Fletcher JA.Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.Cancer Res. 2006 Sep 15;66(18):9153-61.
  16982758
• Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G.Understanding the decisions of cancer clinical trial participants to enter research studies: Factors associated with informed consent, patient satisfaction, and decisional regret.Patient Educ Couns. 2006
  16242898
• Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA.Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.J Clin Oncol.
  16954519
• Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM.Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors.J Clin Oncol. 2006 M
  16710031
• George S, Desai J, Paul Eder J, Manola J, Ryan DP, Appleman LJ, Demetri GD.Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.Eur J Cancer. 2006 May;42(7):864-70.
  16503137
• Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA.Clinical and molecular studies of the effect of imatinib on advanced aggre
  16505440
• Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ,.Clinical Cancer Advances 2005:
  16326753
• Rodgers GM, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Demetri GD, Djulbegovic B, Garst JL, Gore M, Kraut EH, Lin WC, Millenson M, Mock V, Reinke D, Rosenthal J, Sabbatini P.Cancer- and treatment-related anemia.J Natl Compr Canc Netw. 2005
  16316613
• Dileo P, Demetri GD.Update on new diagnostic and therapeutic approaches for sarcomas.Clin Adv Hematol Oncol. 2005 Oct;3(10):781-91.
  16258489
• George S, Hornick JL, Bertagnolli MM, Fletcher CD, Demetri GD.Current management of metastatic gastrointestinal stromal tumor: a case report.Clin Adv Hematol Oncol. 2003 Jan;1(1):63-4; discussion 65.
  16227963
• Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD.Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tis
  16110008
• Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, Lyman GH, Michaud L, Motl S, Vadhan-Raj S, Wong MK,.Myeloid growth factors clinical practice guidelines in oncology.J Natl Compr Canc Net
  16038645
• Griffin JM, Amand MS, Demetri GD.Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.Clin J Oncol Nurs. 2005 Apr;9(2):161-9.
  15853160
• Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, Curiel-Lewandrowski C, Duensing A, van de Rijn M, Schnipper LE, Demetri GD.Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.J Clin Oncol. 2005 Apr 20;23
  15837988
• Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD.Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.Radiology. 2005 Jun;235(3):892-8.
  15833985
• Desai J, Demetri GD.Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.Best Pract Res Clin Haematol. 2005;18(3):389-406.
  15792913
• Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD.
  15781488
• Oliveira AM, Perez-Atayde AR, Dal Cin P, Gebhardt MC, Chen CJ, Neff JR, Demetri GD, Rosenberg AE, Bridge JA, Fletcher JA.Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD
  15735689
• Saund MS, Demetri GD, Ashley SW.Gastrointestinal stromal tumors (GISTs).Curr Opin Gastroenterol. 2004 Mar;20(2):89-94.
  15703627
• McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA.Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Explorat
  15681532
• Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD.Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft ti
  15355900
• Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA.Kinase mutations and imatinib
  14645423
• Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP.Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study.Breast Cancer Res Treat. 2003 Jun;79(3
  12846423
• Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA.PDGFRA activating mutations in gastrointestinal stromal tumors.Science. 2003 Jan 31;299(5607):708-10.
  12522257
• Demetri GD.Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.Hematol Oncol Clin North Am. 2002 Oct;16(5):1115-24.
  12512386
• Ryan DP, Puchalski T, Supko JG, Harmon D, Maki R, Garcia-Carbonero R, Kuhlman C, Winkelman J, Merriam P, Quigley T, Jimeno J, Manola J, Demetri GD.A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.O
  12490740
• Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G.Management of malignant gastrointestinal stromal tumours.Lancet Oncol. 2002 Nov;3(11):655-64.
  12424067
• Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS.A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.Ca
  12416897
• Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, Lopez-Lazaro L, Jimeno J, Guzman C, Supko JG.Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients
  12357306
• Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joen
  12181401
• Demetri GD.ET-743: the US experience in sarcomas of soft tissues.Anticancer Drugs. 2002 May;13 Suppl 1:S7-9.
  12173492
• Demetri GD, Gabrilove JL, Blasi MV, Hill RJ, Glaspy J.Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy.Clin Breast Cancer. 2002 Apr;3(1):45-51.
  12020395
• Glaspy J, Degos L, Dicato M, Demetri GD.Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials.Oncologist. 2002;7(2):126-35.
  11961196
• Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD.Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast ca
  11895894
• Bramwell VH, Morris D, Ernst DS, Hings I, Blackstein M, Venner PM, Ette EI, Harding MW, Waxman A, Demetri GD.Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant
  11839653
• Brooks BJ, Bani JC, Fletcher CD, Demeteri GD.Challenges in oncology. Case 4. Response of metastatic gastrointestinal stromal tumor including CNS involvement to imatinib mesylate (STI-571).J Clin Oncol. 2002 Feb 1;20(3):870-2.
  11821475
• Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA.KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.Cancer Res. 2001 Nov 15;61(22):8118-21.
  11719439
• Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD.STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.Oncogene. 2001 Aug 16;20(36):5054-8.
  11526490
• Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD.Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
  11287975
• Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L.A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemother
  11277174
• Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW.Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.Clin
  11234874
• Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW.Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.Proc Natl Acad Sci U
  10984506
• Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD, Fletcher JA.KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.Am J Pathol. 2000 Mar;156(3):791-5.
  10702394
• Friedberg JW, Van den Abbeele AD, Kehoe K, Singer S, Fletcher CD, Demetri GD.Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma.Cancer. 1999 Oct 15;86(8):1621-7.
  10526294
• Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S.Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.Proc Natl Acad S
  10097144
• Demetri GD, Kris M, Wade J, Degos L, Cella D.Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.J Clin Oncol
  9779721
• Demetri GD, Pollock R, Baker L, Balcerzak S, Casper E, Conrad C, Fein D, Hutchinson R, Schupak K, Spiro I, Wagman L.NCCN sarcoma practice guidelines. National Comprehensive Cancer Network.Oncology (Huntingt). 1998 Jul;12(7A):183-218.
  9699217
• Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA, Menchaca DM, Gringeri AJ, Schwartz LB, Galli SJ.Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo.J Exp M
  8676090
• Singer S, Baldini EH, Demetri GD, Fletcher JA, Corson JM.Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival.J Clin Oncol. 1996 Apr;14(4):1201-8.
  8648375
• Demetri GD, Elias AD.Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.Hematol Oncol Clin North Am. 1995 Aug;9(4):765-85.
  7490240
• Singer S, Corson JM, Demetri GD, Healey EA, Marcus K, Eberlein TJ.Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma.Ann Surg. 1995 Feb;221(2):185-95.
  7857146
• Salgia R, Demetri GD, Kaplan WD.Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemothera
  7521785
• Demetri GD.The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer.Hematol Oncol Clin North Am. 1994 Feb;8(1):233-49.
  8150782
• Demetri GD.Impact of hematopoietic growth factors on the management of small-cell lung cancer.Chest. 1993 Apr;103(4 Suppl):427S-432S.
  8384974
• Demetri GD.Hematopoietic growth factors: current knowledge, future prospects.Curr Probl Cancer. 1992 Jul-Aug;16(4):177-259.
  1382921
• Demetri GD, Griffin JD.Granulocyte colony-stimulating factor and its receptor.Blood. 1991 Dec 1;78(11):2791-808.
  1720034
• Demetri GD, Ernst TJ, Pratt ES, Zenzie BW, Rheinwald JG, Griffin JD.Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes.J Clin Invest. 1990 Oct;86(4):1261-9.
  2212010
• Sharkis SJ, Jones RJ, Bellis ML, Demetri GD, Griffin JD, Civin C, May WS.The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors.Blood. 1990 Aug 15;76(4):716-20.
  2200537
• Bauer KA, Conway EM, Bach R, Konigsberg WH, Griffin JD, Demetri G.Tissue factor gene expression in acute myeloblastic leukemia.Thromb Res. 1989 Nov 1;56(3):425-30.
  2617479
• Demetri GD, Spriggs DR, Sherman ML, Arthur KA, Imamura K, Kufe DW.A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo.J Clin Oncol. 1989 Oct;7(10):1545-53.
  2506316
• Demetri GD, Zenzie BW, Rheinwald JG, Griffin JD.Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro.Blood. 1989 Aug 15;74(3):940-6.
  2787682
• Brouckaert P, Spriggs DR, Demetri G, Kufe DW, Fiers W.Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma.J Exp Med. 1989 Jun 1;169(6):2257-62.
  2499657